Session 7: VICH Conference

Slides:



Advertisements
Similar presentations
Mandate and Terms of Reference of the CEWG. The Presentation Background Mandate from the Resolution Points requiring clarity Resolution WHA63.28.
Advertisements

Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Dublin Airport Stakeholders Forum Workshop 28 November 2007.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
IPCC Products, Procedures and Processes Amsterdam, 14 May 2010 Dr. Renate Christ, Secretary of the IPCC.
Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
1 IPCC IAC Review meeting R.K. Pachauri Chairman, Intergovernmental Panel on Climate Change Amsterdam, May 14, 2010 WMO UNEP.
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Safeguarding Animal Health 1 Proposed BSE Comprehensive Rule: A New Approach to BSE Rulemaking Dr. Christopher Robinson Assistant Director, NCIE BSE Comprehensive.
. Summary of the consultation on the CES Census Recommendations Conference of European Statisticians 17 June 2015.
Chemical Industries Council of Malaysia Responsible Care  APEC CHEMICAL DIALOGUE 9th Asia Pacific Responsible Care Conference November 16, 2005 * EDSA.
OIE standards and recommendations for Veterinary Education and VSB’s and their role in good governance Dr Dietrich Rassow Advisor Scientific and Technical.
Letter of intent By to predefined format (Word file, see guidelines) Chair Scientific Committee Coordination EO To all members of.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Development and application of guidance documents – industry view Dr Martin Schaefer ECCA-ECPA Conference March 2014.
REVIEW OF THE RCA AGREEMENT 2013 RCARO Workshop on Strengthening the RCA/RCARO Activities and its Efficiency, 7-9 August 2013, Seoul, South Korea Alumanda.
MULTILATERAL COOPERATION KEY PERFORMANCE AREAS SA engagement with the UN Implementation of major summits and international conventions relevant to S&T.
Slide: 1 Osamu Ochiai Water SBA Coordinator The GEO Water Strategy Report – The CEOS Contribution Presentation to the 26 th CEOS Plenary at Bengaluru,
The Codex Alimentarius Commission
Review of the Gothenburg Protocol: WGSR Conclusions Review of the Gothenburg Protocol: WGSR Conclusions 8th Joint TFEIP/EIONET Meeting Dublin, October.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
Introduction to the UNCCD Strategy, new monitoring and assessment system and relevant COP decisions Training of Trainers Rome, 31 May – 4 June 2010.
Task NumberHarmonise, develop & implement capacity building Performance Indicators CB-07-01c Harmonise efforts by Tasks, in particular those related with.
Department of Labour Presentation of ILO 93 rd Conference to the Portfolio Committee on Labour 8 November 2005.
The Data Sharing Working Group 24 th meeting of the GEO Executive Committee Geneva, Switzerland March 2012 Report of the Data Sharing Working Group.
EVALUATION OF THE SEE SARMa Project. Content Project management structure Internal evaluation External evaluation Evaluation report.
Reliability Standards Development Plan David Taylor Manager Standards Development Standards Committee Meeting June 12-13, 2008.
Danish experience in the participation in the OIE standard setting process Regional Information Seminar for Recently Appointed OIE Delegates Brussels (Belgium),
Revision of the UN FDES United Nations Statistics Division.
Pre-application process in England and Wales Sixth meeting of the Task Force on Public Participation in Decision- making under the Aarhus Convention
Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.
VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
VICH Outreach Forum Stability Studies to address climatic zones III and IV Mai Huynh US FDA/Center for Veterinary Medicine October 26-27, 2015.
Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.
Challenges of Developing VICH Guidance for Residue Studies in Food Producing Aquatic Species Pamela Boner, Zoetis Session 7: VICH Conference Tokyo, Japan:
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.
VICH Task Force for Efficacy Studies for Combination Products Progress Report (Final) VICH members JMAFF (chair)K. Noda JVPAE. Oishi IFAH-EUM. Bobey EUK.
Reports foreseen within Task 21 Task 21 Experts meeting, Seoul 20 April 2011 Harry Vreuls Operating Agent.
EIAScreening6(Gajaseni, 2007)1 II. Scoping. EIAScreening6(Gajaseni, 2007)2 Scoping Definition: is a process of interaction between the interested public,
1 THE OIE REPORT 32 nd VICH SC Meeting / 6 th VICH Outreach Forum Meeting Jean-Pierre Orand, Anses, France, OIE Collaborating Centre.
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
Participatory Monitoring and Evaluation of Community Projects – A Model Pretoria, South Africa 30 November – 3 December 2009.
UNEP Training Resource ManualTopic 9 Slide 1 No EIA EIA Required *Public involvement Scoping Mitigation and impact management EIA Report Proposal Identification.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Update of Results of the Survey on training Priorities
STABILITY ?.
Hervé Marion, DVM VICH Secretariat
VICH General Principles and
The Codex Alimentarius Commission
Introduction to the UNCCD Strategy, new monitoring and assessment system and relevant COP decisions Training of Trainers Rome, 31 May – 4 June 2010.
Expert Meeting Methods for assessing current and future coastal vulnerability to climate change 27 – 28 October 2010 Draft conclusions.
STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) & ASSIGNING RETEST PERIOD OF API’S January, 2015.
The OIE report 30th VICH SC Meeting / 4th VICH Outreach Forum Meeting
The GEO-6 Matrix Drafting Approach
Report by the VICH Steering Committee on issues raised by Forum members during the 1st Outreach Forum meeting Hervé Marion, DVM VICH Secretariat.
WHO Technical Report Series, No. 953, 2009
Recommendations from the Stage 3 Trial Review
OIE standards and recommendations
SSG on WFD and agriculture
D 4 Food webs Process: two open workshops WGGES consultation
The Benefits of VICH to Emerging Countries
WFD, Common Implementation Strategy   Water Scarcity and Droughts Expert Network Brussels, July 2, 2009.
WG GES: Decision review progress
Alignment of Part 4B with ISAE 3000
Hervé Marion, DVM VICH Secretariat
Presentation transcript:

Session 7: VICH Conference Development of VICH Guidance on Stability Studies To Address Climatic Zones III and IV Dr A T Sigobodhla Session 7: VICH Conference Tokyo, Japan: 27 – 29 October 2015

Introduction Background Conclusion Problem statement Current situation PRESENTATION OUTLINE Introduction Background Problem statement Current situation Work done, comments and glimpse of the OIE survey Conclusion

Introduction: Purpose of stability testing To provide evidence on how quality of the Active Pharmaceutical Ingredient (API) or Final Product (FP) varies under the influence of: a. Temperature b. Relative humidity c. Light/moisture (if applicable) 2. Establish a re-test period for the API or shelf life for the FP Stability chambers

Background Topic proposed: IFAH-Europe in 2010 Problem statement: current VICH GL 3 on stability addresses requirements for climatic zones I and II only Implications: No “common” document or common consensus addressing requirements for climatic zones III & IV Differences in testing conditions between countries in the same zone

Progress made since November 2013 29th VICH SC Meeting : recommended that more work was required before SC can make a decision Task Force was formed 1st half of 2014: OIE Survey: Collected information from OIE member countries on their current stability testing conditions and their willingness to contribute to this amendment Task Force considered comments received Expert Working Group was formed

Mandate of the Expert Working Group Recommendations at the 31st VICH SC meeting: Quality EWG to continue with the work initiated by TF and seek good representation of experts from VOF regions with active involvement from Asia, Africa and Latin America EWG to develop a basic guidance that is a stand alone document not a revision of current GL3 Keep new guideline simple, with a stepwise approach for further development It was hoped that South Africa and Australia could contribute to the work

Examples of Comments received and to be considered

Benefits Eliminate current discrepancies within the zones: harmonisation of testing conditions mandatory The Proposed stand alone Guidance on stability studies for climatic zones III and IV, in conjunction with VICH GL3 (R) will be a single source for VICH and non-VICH countries alike Clarity and predictability on technical requirements for stability testing in climatic zones III/IV – no additional studies and specific negotiations needed Increased product availability Solid, scientifically based criteria readily usable for evaluation by regulatory agencies

Long-term Testing Conditions WHO climatic zones Climatic zone Definition Criteria Mean annual temperature measured in the open air/ Mean annual partial water vapour pressure Long-term Testing Conditions I Temperate climate ≤ 15 °C / ≤ 11 hPa 21 °C / 45% RH II Subtropical & Mediterranean climate > 15 to 22 °C / > 11 to 18 hPa 25 °C / 60% RH III Hot and dry climate > 22 °C / ≤ 15 hPa 30 °C / 35% RH IVA Hot and humid climate > 22 °C / > 15 to 27 hPa 30 °C / 65% RH IVB Hot and very humid climate > 22 °C / > 27 hPa 30 °C / 75% RH

Application of WHO GL to Animal Health? 1. Climatic zones Require clear definitions, incl. scientific criteria to be applied for stability evaluation Important differences between Animal and Human health with regards to dosage forms (impact of packaging on moisture (non-)uptake) Duration of long-term stability data for regulatory submission (VICH 6 months vs. WHO 12 months) Lack of harmonisation of WHO GL within regions Consider in particular, the impact that the GL could have on the shelf life of products in other climatic zones (Zone I and II).

Conclusion The SC reviewed the results of the OIE Survey regarding potential acceptance of a VICH guideline on stability testing for climatic zones III and IV and noted; many of the respondents with relevant climatic zones indicated a willingness to use such a VICH guideline and many respondents are prepared to provide input into the VICH activity. sufficient assurance was provided that a VICH guideline considering stability for climatic zones III and IV would be used by non-VICH countries.